Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mesothelioma Stratified Therapy (MiST): A Stratified Multi-arm Phase IIa Clinical Trial to Enable Accelerated Evaluation of Targeted Therapies for Relapsed Malignant Mesothelioma

Next Previous
Search
Trial Profile

Mesothelioma Stratified Therapy (MiST): A Stratified Multi-arm Phase IIa Clinical Trial to Enable Accelerated Evaluation of Targeted Therapies for Relapsed Malignant Mesothelioma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abemaciclib (Primary) ; Atezolizumab (Primary) ; Bemcentinib (Primary) ; Bevacizumab (Primary) ; Dostarlimab (Primary) ; Niraparib (Primary) ; Pembrolizumab (Primary) ; Rucaparib (Primary)
  • Indications Malignant-mesothelioma
  • Focus Therapeutic Use
  • Acronyms MiST; MIST3

    • Most Recent Events

    • 04 Jun 2024 Results (n=26) presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2023 Results assessing knowledge gap through multi-omic interrogation of tumours from patients enrolled into arm 4 of this trial, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2023 Results (n=26) assessing cellular and molecular correlates of efficacy in patients with relapsed mesothelioma presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top